Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (221-230 of 703) with videos related to

Pageof 71
Sort By:
Pigment Cell & Melanoma Research|December 27, 2017
Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapyMartin Tio, Xuan Wang, Matteo S Carlino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2011
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanomaJames S Wilmott, Georgina V Long, Julie R Howle, et al.
Asia-Pacific Journal of Clinical Oncology|December 2, 2016
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologistsVictoria Atkinson, Georgina V Long, Alexander M Menzies, et al.
Plos One|April 16, 2014
Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signalingAndy J Chien, Lauren E Haydu, Travis L Biechele, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 14, 2022
Reflectance confocal microscopy - a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanomaG Ho, R J Schwartz, A Regio Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2012
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanomaAlexander M Menzies, Lauren E Haydu, Lydia Visintin, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapyWei Yen Chan, Jenny H Lee, Ashleigh Stewart, et al.
Pigment Cell & Melanoma Research|November 25, 2017
Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanomaJenny H J Lee, Megan Lyle, Alexander M Menzies, et al.
The Journal of Clinical Endocrinology and Metabolism|April 20, 2021
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor TreatmentChristopher A Muir, Roderick J Clifton-Bligh, Georgina V Long, et al.
Future Oncology (London, England)|September 4, 2023
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanomaAlexander Cj van Akkooi, Axel Hauschild, Georgina V Long, et al.
Pageof 71

Showing results (221-230 of 703) with videos related to

Sort By:
Pageof 71
Pigment Cell & Melanoma Research|December 27, 2017
Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapyMartin Tio, Xuan Wang, Matteo S Carlino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2011
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanomaJames S Wilmott, Georgina V Long, Julie R Howle, et al.
Asia-Pacific Journal of Clinical Oncology|December 2, 2016
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologistsVictoria Atkinson, Georgina V Long, Alexander M Menzies, et al.
Plos One|April 16, 2014
Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signalingAndy J Chien, Lauren E Haydu, Travis L Biechele, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 14, 2022
Reflectance confocal microscopy - a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanomaG Ho, R J Schwartz, A Regio Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2012
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanomaAlexander M Menzies, Lauren E Haydu, Lydia Visintin, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapyWei Yen Chan, Jenny H Lee, Ashleigh Stewart, et al.
Pigment Cell & Melanoma Research|November 25, 2017
Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanomaJenny H J Lee, Megan Lyle, Alexander M Menzies, et al.
The Journal of Clinical Endocrinology and Metabolism|April 20, 2021
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor TreatmentChristopher A Muir, Roderick J Clifton-Bligh, Georgina V Long, et al.
Future Oncology (London, England)|September 4, 2023
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanomaAlexander Cj van Akkooi, Axel Hauschild, Georgina V Long, et al.
Pageof 71